Moleculin Biotech, Inc. (MBRX): Depreciation & Amortization
$90.0K
Year ended 2025-12-31
$47.0K
Trailing 12 months to 2026-06-30
-11.5%
3-year compound annual growth
-14.8%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.0K | -28.6% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $126.0K | -0.8% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $127.0K | -2.3% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $130.0K | -20.7% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $164.0K | -18.0% | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | $200.0K | +0.5% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $199.0K | +192.6% | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | $68.0K | +277.8% | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | $18.0K | +200.0% | 2019-02-21, From 2017-01-01 |
| 2016-12-31 | $6.0K | n/a | 2018-03-28, From 2016-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $90.0K | -28.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare MBRX, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗